Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs iShares Global Clean Energy ETF (ICLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs iShares Global Clean Energy ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.81 (market cap $8.04B), while iShares Global Clean Energy ETF trades at $18.93. Which is the better fit depends on your goals.
| BIO | ICLN | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | — |
52-Week High | $339.75 | $23.75 |
52-Week Low | $241.71 | $13.41 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
ICLN, the iShares Global Clean Energy ETF, trades at $18.625, down 3.25% on the day, with technical indicators showing a bearish trend. The ETF holds 105 global renewable energy companies and has delivered strong year-to-date performance, driven by increased energy demand and policy support. Recent news highlights comparisons with traditional energy and uranium ETFs, emphasizing ICLN's growth focus versus income alternatives.
Outlook remains mixed: clean energy benefits from structural trends like AI-driven power demand and global decarbonization goals, but risks include regulatory uncertainty and high volatility. The ETF's valuation and growth potential appeal to long-term investors, though near-term price action suggests caution amid bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →
